Based on these premises, it might be attempted to extrapolate the results obtained in the mouse models described here to design a clinical trial in which NSCLC patients would receive standard chemotherapy in combination with crizotinib (and this independently of the status of ALK and ROS1), followed by ICB. This evidence concerns the gene ALK and non-small cell lung carcinoma.